Literature DB >> 14725628

The antiepileptic drug levetiracetam selectively modifies kindling-induced alterations in gene expression in the temporal lobe of rats.

Jessie Gu1, Berkley A Lynch, Dina Anderson, Henrik Klitgaard, Sun Lu, Michael Elashoff, Ulrich Ebert, Heidrun Potschka, Wolfgang Löscher.   

Abstract

Gene expression profiling by microarrays is a powerful tool for identification of genes that may encode key proteins involved in molecular mechanisms underlying epileptogenesis. Using the Affymetrix oligonucleotide microarray, we have surveyed the expression levels of more than 26,000 genes and expressed sequence tags (ESTs) in the amygdala-kindling model of temporal lobe epilepsy. Furthermore, the effect of the antiepileptic drug levetiracetam (LEV) on kindling-induced alterations of gene expression was studied. Treatment of rats with LEV during kindling acquisition significantly suppressed kindling development. For gene expression profiling, six groups of rats were included in the present study: (i) and (ii) sham-operated rats treated with saline or LEV; (iii) and (iv) electrode-implanted but non-kindled rats treated with saline or LEV; (v) and (vi) kindled rats treated with saline or LEV. Treatment was terminated after 11 or 12 daily amygdala stimulations, when all vehicle-treated rats had reached kindling criterion, i.e. a stage 5 seizure. Twenty-four hours later, the ipsilateral temporal lobe was dissected for mRNA preparation. Six temporal lobe preparations from each group were analysed for differential gene expression. In control (non-kindled) rats, LEV treatment was devoid of any significant effect on gene expression. In saline-treated kindled rats, a large number of genes were observed to display mRNA expression alterations compared with non-kindled rats. LEV treatment induced marked effects on gene expression from kindled rats. Previously described epilepsy-related genes, such as neuropeptide Y (NPY), thyrotropin-releasing hormone (TRH) and glial fibrillary acidic protein (GFAP) were confirmed to be up-regulated by kindling and partially normalized by LEV treatment. Real-time quantitative polymerase chain reaction confirmed NPY, TRH and GFAP expression data from chip experiments. Furthermore, a number of novel genes were identified from the gene chip experiments. A subgroup of these genes demonstrated correlation between expression changes and kindled phenotype measurements. In summary, this study identified many genes with potentially important roles in epileptogenesis and highlighted several important issues in using the gene chip technology for the study of animal models of CNS disorders.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14725628     DOI: 10.1111/j.0953-816x.2003.03106.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  15 in total

Review 1.  Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research.

Authors:  Wolfgang Löscher; Claudia Brandt
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

2.  SV2A: more than just a new target for AEDs.

Authors:  Asla Pitkänen
Journal:  Epilepsy Curr       Date:  2005 Jan-Feb       Impact factor: 7.500

3.  Region-specific changes in gene expression in rat brain after chronic treatment with levetiracetam or phenytoin.

Authors:  Bjørnar Hassel; Erik Taubøll; Renee Shaw; Leif Gjerstad; Ray Dingledine
Journal:  Epilepsia       Date:  2010-09       Impact factor: 5.864

4.  Efficacy and safety of Levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastoma.

Authors:  Andrés F Cardona; Leonardo Rojas; Beatriz Wills; Laura Bernal; Alejandro Ruiz-Patiño; Oscar Arrieta; Enrique Jiménez Hakim; Fernando Hakim; Juan Armando Mejía; Nicolás Useche; Sonia Bermúdez; Hernán Carranza; Carlos Vargas; Jorge Otero; Luis Carlos Mayor; León Darío Ortíz; Sandra Franco; Carlos Ortíz; Miguel Gil-Gil; Carmen Balaña; Zyanya Lucia Zatarain-Barrón
Journal:  J Neurooncol       Date:  2017-11-25       Impact factor: 4.130

Review 5.  The potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments.

Authors:  Rafal M Kaminski; Michael A Rogawski; Henrik Klitgaard
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

Review 6.  Synaptic vesicle protein 2: A multi-faceted regulator of secretion.

Authors:  Kristine Ciruelas; Daniele Marcotulli; Sandra M Bajjalieh
Journal:  Semin Cell Dev Biol       Date:  2019-03-21       Impact factor: 7.727

7.  Levetiracetam inhibits Na+-dependent Cl-/HCO3- exchange of adult hippocampal CA3 neurons from guinea-pigs.

Authors:  Tobias Leniger; Jan Thöne; Udo Bonnet; Andreas Hufnagel; Dieter Bingmann; Martin Wiemann
Journal:  Br J Pharmacol       Date:  2004-07-12       Impact factor: 8.739

Review 8.  Attenuation of kindled seizures by intranasal delivery of neuropeptide-loaded nanoparticles.

Authors:  Michael J Kubek; Abraham J Domb; Michael C Veronesi
Journal:  Neurotherapeutics       Date:  2009-04       Impact factor: 7.620

9.  Early life stress as an influence on limbic epilepsy: an hypothesis whose time has come?

Authors:  Amelia S Koe; Nigel C Jones; Michael R Salzberg
Journal:  Front Behav Neurosci       Date:  2009-10-05       Impact factor: 3.558

10.  Levetiracetam attenuates hippocampal expression of synaptic plasticity-related immediate early and late response genes in amygdala-kindled rats.

Authors:  Kenneth V Christensen; Henrik Leffers; William P Watson; Connie Sánchez; Pekka Kallunki; Jan Egebjerg
Journal:  BMC Neurosci       Date:  2010-01-27       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.